PICTET ASSET MANAGEMENT LTD - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 155 filers reported holding SAGE THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 1.15 and the average weighting 0.3%.

Quarter-by-quarter ownership
PICTET ASSET MANAGEMENT LTD ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q2 2021$209,000
-30.1%
3,684
-7.9%
0.00%
Q1 2021$299,000
-21.5%
4,000
-9.1%
0.00%
Q4 2020$381,000
+41.6%
4,4000.0%0.00%
Q3 2020$269,000
-87.8%
4,400
-94.3%
0.00%
-100.0%
Q1 2020$2,213,000
-91.0%
77,056
-77.3%
0.01%
-88.4%
Q4 2019$24,523,000
-63.3%
339,698
-28.6%
0.04%
-38.6%
Q3 2019$66,760,000
-11.2%
475,870
+15.9%
0.07%
-56.8%
Q2 2019$75,190,000
+6.3%
410,672
-7.6%
0.16%
+3.8%
Q1 2019$70,709,000
+62.6%
444,572
-2.1%
0.16%
+43.1%
Q4 2018$43,493,000
-21.4%
454,044
+16.0%
0.11%
-6.8%
Q3 2018$55,306,000
-7.3%
391,548
+2.7%
0.12%
-18.2%
Q2 2018$59,684,000
-4.9%
381,291
-2.1%
0.14%
-7.7%
Q1 2018$62,733,000
-18.9%
389,479
-17.1%
0.16%
-22.1%
Q4 2017$77,350,000
+227.5%
469,610
+23.9%
0.20%
+197.0%
Q3 2017$23,615,000
-25.6%
379,045
-21.0%
0.07%
-31.6%
Q2 2017$31,734,000
+4.4%
480,013
+12.2%
0.10%
-1.0%
Q1 2017$30,410,000
+102.9%
427,889
+45.8%
0.10%
+76.8%
Q4 2016$14,988,000
-5.2%
293,542
-14.5%
0.06%
-5.1%
Q3 2016$15,815,000
+10.1%
343,429
-21.3%
0.06%
+5.4%
Q2 2016$14,367,000
+1083.4%
436,538
+957.0%
0.06%
+1020.0%
Q1 2016$1,214,00041,3000.01%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q3 2016
NameSharesValueWeighting ↓
Finepoint Capital LP 475,600$15,362,0005.31%
Integral Health Asset Management, LLC 412,257$13,316,0002.74%
Palo Alto Investors LP 851,409$27,501,0002.40%
Boxer Capital, LLC 1,094,000$35,336,0002.24%
DAFNA Capital Management LLC 180,306$5,824,0001.59%
Ikarian Capital, LLC 250,000$8,075,0001.47%
Bellevue Group AG 2,973,178$96,034,0001.36%
SECTOR GAMMA AS 118,476$3,827,0000.86%
Artal Group S.A. 450,000$14,535,0000.78%
Diametric Capital, LP 19,393$626,0000.46%
View complete list of SAGE THERAPEUTICS INC shareholders